Objective: To assess the cost-effectiveness of pharmaceutical care (PC) intervention versus usual care (UC) in the management of type 2 diabetes. Methods: This study was a randomized, controlled study with a 12-month patient follow-up in two Nigerian tertiary hospitals. One hundred and ten patients were randomly assigned to each of the "intervention" (PC) and the "control" (UC) groups. Patients in the UC group received the usual/conventional care offered by the hospitals. Patients in the PC group received UC and PC in the form of structural self-care education and training for 12 months. The economic evaluation was based on patients' perspective. Costs of management of individual complications were calculated from activities involved in their management by using activity-based costing. The impact of the interventions on quality of life was estimated by using the HUI23-S4EN.40Q (Mark index 3) questionnaire. The primary outcomes were incremental cost-utility ratio and net monetary benefit. An intentionto-treat approach was used. Two-sample comparisons were made by using Student's t tests for normally distributed variables data at baseline, 6 months, and 12 months. Comparisons of proportions were done by using the chi-square test. Results: The PC intervention led to incremental cost and effect of Nigerian naira (NGN) 10,623 ($69) and 0.12 quality-adjusted life-year (QALY) gained, respectively, with an associated incremental cost-utility ratio of NGN 88,525 ($571) per QALY gained. In the cost-effectiveness acceptability curve, the probability that PC was more cost-effective than UC was 95% at the NGN 250,000 ($1613) per QALY gained threshold and 52% at the NGN 88,600 ($572) per QALY gained threshold. Conclusions: The PC intervention was very cost-effective among patients with type 2 diabetes at the NGN 88,525 ($571.13) per QALY gained threshold, although considerable uncertainty surrounds these estimates.
Introduction
Analytic techniques used for economic evaluation in health care, for example, cost-benefit analysis, cost-effectiveness analysis, and cost-consequences analysis, are designed to compare alternative courses of action in terms of costs and outcomes. The choice of the technique depends on the decision the health economists intend to influence. Quality-adjusted life-years (QALYs) measure health as a combination of the duration of life and the health-related quality of life [1] . The primary outcome of a cost-utility analysis is the cost per QALY, or incremental costutility ratio (ICUR), which is calculated as the difference in the expected cost of two interventions divided by the difference in the expected QALYs produced by the two interventions. The results of a cost-utility analysis are compared with a threshold incremental cost-effectiveness ratio (ICER); interventions with an ICER below this threshold are funded, whereas those with an ICER above the threshold tend not to be. Economic evaluations using QALYs as the principal measure of outcome, often termed cost-utility studies, have become increasingly popular in the literature and have also been adopted by a number of health technology assessment agencies as the methodology of choice [1] .
Cost-utility analysis was developed to help decision makers compare the value of alternative interventions that have very different health benefits, and it facilitates these comparisons without recourse to placing monetary values on different health states. Cost-utility analysis specifies what value is attached to specific health states, and thus increasingly facilitates the transparency of resource allocation processes [2] .
Cost-utility analysis was developed to address the problem of conventional cost-effectiveness analysis, which did not allow decision makers to compare the value of interventions for different health problems. The utilities can now be obtained from standardized and validated health status instruments, making the evidence required to inform cost-utility analysis relatively straightforward and cheap to acquire-certainly when compared with the cost of acquiring evidence on clinical effectiveness, and indeed the cost of many of the treatments being reviewed [3] .
Diabetes mellitus (DM) is associated with considerable morbidity and mortality [4] . It is also a major risk factor for cardiovascular disease, stroke, and kidney failure [5] . In Africa, DM probably has the highest morbidity and mortality rates of all chronic noninfective diseases [6] .
DM was once regarded as a disease of the affluent, but it is now vastly visible as a growing health problem in developing economics because almost 80% of diabetes deaths occur in lowand middle-income countries [7, 8] . The national standardized prevalence rate of DM in Nigeria is 2.2%, while the crude prevalence rate is 7.4% in those aged 45 years and above who live in urban areas [9] . Global estimates of the prevalence of diabetes showed that the prevalence of diabetes in Nigeria in 2010 was 4.7% (vs. 3.9% for world population) and that it would be 5.5% (vs. 4.3% for world population) in 2030 [10] .
With the increasing demand for better management of type 2 diabetes, attention has focused on the potential benefits of pharmaceutical care (PC) to improve patients' health outcomes. Many PC programs have been established in various countries to enhance clinical outcomes and the health-related quality of life. These programs were implemented by pharmacists, with the cooperation of physicians and other health care professionals. PC and the expanded role of pharmacists are associated with many positive diabetes-related outcomes, including improved clinical measures [11] , improved patient and provider satisfaction [12, 13] , and improved cost of management [12, 14] . The pharmacists can, therefore, in collaboration with physicians and other health care professionals, contribute to an improvement in the quality of life of patients with diabetes by informing and educating patients, answering their questions, and, at the same time, monitoring the outcomes of their treatment [15] . In view of the above issues, the objective of this study was to assess the cost-effectiveness of the PC intervention in the management of type 2 diabetes versus usual care (UC).
Methods

Study Design
This study was a randomized, controlled, and longitudinal prospective study with a 12-month patient follow-up. The study followed the Consolidated Health Economic Evaluation Reporting Standards guideline for reporting economic evaluation of interventions [16] . The study protocol was approved by the Research Ethical Committees of the University of Nigeria Teaching Hospital, Ituku Ozalla, and Nnamdi Azikiwe University Teaching Hospital, Nnewi, in which this study was conducted. These hospitals are tertiary hospitals that serve as referral centers to most of the hospitals in the southeastern part of Nigeria.
Inclusion Criteria
Patients with type 2 DM who fulfilled the entrance criteria were identified and included in the study. Inclusion criteria included patients with type 2 diabetes who were on oral hypoglycemic therapy and provided written informed consent in addition to willingness to abide by the rules of the study and being certified fit to take part by the consulting physician.
Exclusion criteria were patients who were diagnosed with type 1 diabetes (to avoid complexity in the scope of the study), patients who were younger than 18 years (they are legally regarded as dependents and consequently they cannot take decisions of their own), patients who were pregnant (they are generally not allowed to participate in a study of this nature by the institutions used for the study), and patients who expressed willingness to withdraw from the study (participation is voluntary). The sample size determination showed that a sample size of at least 104 patients was required in each of the control and intervention groups [17] . Based on these data, to ensure sufficient statistical power and to account for "dropouts" during the study, a target sample size of 220 patients was recruited (110 patients from each of the hospitals). The folders of the 110 selected patients in each hospital were assigned numbers 1 to 110, which represented an individual patient. Patients were randomly assigned to one of two groups (intervention group or control group) on the basis of the number assigned to their folders by using online "random sequence generator" [18] with sequence boundaries of 1 to 110 (boundaries inclusive) set in a two-column format: the first column was a priori designated to the intervention group PC (55 patients) and the second column to the control group UC (55 patients).
Patients in the UC group received the usual/conventional care offered by the hospitals, which included hospital visits on appointment or on a sick day, consultations with physicians, prescription of drugs and routine laboratory tests, review of diagnosis and medications, refilling of prescriptions by patients, and referral. This UC was offered with education/training of the patients in an uncoordinated manner and without structured educational materials. Patients in the PC group received UC and PC for 12 months on monthly schedule. This additional PC included a stepwise approach: setting priorities for patient care, assessing patients' specific educational needs and identification of drug-related problems, development of a comprehensive and achievable PC plan in collaboration with the patient and the physician, implementation of this plan, and monitoring and review of the plan from time to time [19] . The nurses collaborated with the pharmacists in terms of organizing the patients and patients' folders, taking point-of-care testing, counseling the patients, and reinforcing the information given to the patients during training sections. The physicians provided the visitation/appointment schedule for the patients, and prescription of laboratory tests. They were also involved in the implementation of consensus strategies in managing drug-related problems in areas of changing, substitution, and withdrawal of medications. All the members of the health care team were trained before the implementation of the intervention.
The medical and educational contents of the training materials were evaluated by the physicians and nurses in diabetes clinics before the researchers conducted the training for the patients. The physicians and nurses were asked to rate the materials as being excellent, very good, good, fair, poor, and useless.
The monthly educational/training program for the patients consisted of four sections of 90 to 120 minutes. The program covered the following areas: diabetes overview and its complications, self-monitoring blood glucose techniques and interpretation of diabetes-related tests, medications and their side effects, lifestyle modification, counseling, and effective interaction with health providers. PC provided ground for the patients to monitor and react to changes in their blood glucose levels, allowing them to integrate their diabetes into the lifestyle they preferred.
Data Collection
Data were collected on utilization of health care resources for 12 months for control and intervention groups at baseline, 6 months, and 12 months. Information was obtained on the frequency of self-monitoring, number and average duration of visits to a hospital, daily doses of drugs taken regularly, and the variable of "other health care resource use," including primary care (general practitioner and nurse consultations), hospital care (visits to an accident and emergency department, outpatient care, day hospital care, and inpatient care), auxiliary health care (services of a podiatrist, optician, or dietitian), and private health care. These data were collected by means of patients' PC diaries notes supplemented when necessary by information from patients' medical records.
Patient-specific data on the incremental resources required for intervention and control groups and the resources associated with the treatment of complications were taken. Treatment resources included doses of drugs used for treating diabetes, antihypertensive drugs, other drugs, blood-glucose tests, selfmonitoring resources such as test strips, lancets, and glucometers, and visits to general practitioners, practice nurses, and clinics. Resources associated with complications included the number, duration, and specialty of admissions to hospital; outpatient consultations; medical procedures such as photocoagulation and cataract extraction; and day case episodes. The unit cost of these resource volumes (drugs and other consumables, laboratory tests, and specialty care per visit) was derived by using the National Health Insurance Scheme price list [20] and International Drug Price Indicator Guide 2010 edition [21] , and the cost of all inpatient bed-days and outpatient visits was derived from World Health Organization-Choosing Intervention that is CostEffective (WHO-CHOICE) [22] unit-cost estimates. Costs of the management of individual complications were calculated from activities involved in their management by using the ingredient approach or activity-based costing as opined by the experts; all costs were adjusted to 2011 cost [23] . The effect of either a higher or lower adjustment rate was examined in the sensitivity analysis. All costs are reported in year 2011 values of Nigerian naira (NGN 155 ¼ $1).
Each item for resource use was categorized into the "cost of the intervention," the "cost of drugs," and the "cost of other health care resource use" (including primary care, hospital care, and auxiliary health care). The costs were calculated by multiplying the volume of resource use in each category by the associated unit cost in 2010 prices (Table 1) . Average costs were estimated in each arm of the study for the 12 months of follow-up Table 2 .
The impact of the interventions on quality of life was estimated by using the HUI23S4EN.40Q (developed by HUIncMark index 2&3) questionnaire at baseline, 6 months, and 12 months in accordance with the HUI procedures manual (HUI23-S4EN.40Q, HUI23-40Q.MNL) [24] . We adopted the QALY [2] because this measure captures both increases in life expectancy and improved quality of life that results from the prevention of complications, providing a composite outcome measure of fatal and nonfatal events that permits comparison between many health interventions.
Because the economic evaluation perspective was that of the health care purchaser, only direct health service costs were included. These included treatment costs, visits to a nurse or a general practitioner based on "standard practice" assumptions, and costs of treating diabetes complications. Not included in this analysis were nonmedical costs such as out-of-pocket expenses incurred when visiting clinics, cost of informal care provided by family members, and production losses resulting from work absences, long-term disability, or premature death.
Statistical Analysis
Statistical analyses were performed by using the SPSS package, version 14 (SPSS, Inc., Chicago, IL). An intention-to-treat approach was used. Data were summarized as means Ϯ SD, mean differences with 95% confidence intervals. Two-sample comparisons were made by using Student's t tests for normally distributed variables or Mann-Whitney U tests for nonnormally distributed data (0, 6, and 12 months). Comparisons of proportions were carried out by using chi-square, Fisher's exact, or McNemar's tests. An a priori significance level of P less than 0.05 was used throughout. Based on the overall health-related quality-of-life score for the patients at baseline, 6 months, and 12 months, QALYs were determined. Areas under the curves were determined by using WinNonlin standard edition version 2.1 [3, 22] .
Sensitivity analysis
To address uncertainty around the ICUR, univariate sensitivity analysis was conducted, where one cost variable was varied at a time (upper and lower limits) while keeping all other variables constant at their mean base-case cost. Then, two alternative-case outcomes of ICUR were generated on the basis of upper and lower boundaries of Ϯ20% of the mean base-case cost.
To assess how a simultaneous change in several variables (QALYs, total intervention cost, cost of antidiabetes medications, cost of antihypertensives, cost of antidiabetes antihypertensives medications, total cost of drugs, hospital care cost, auxiliary health care cost) affects the cost-utility ratio, a Monte-Carlo simulation (a type of multivariate sensitivity analysis) was performed. This technique runs a large number of simulations (here 1000) by repeatedly drawing samples from probability distributions of input variables. Thus, it provides a probability distribution of the output variable; that is, QALYs, incremental costs, incremental effectiveness, and ICURs. Beta and gamma distributions were assumed for utility (QALYs) and unit cost, respectively [25] [26] [27] .
Given that the interpretation of negative ICURs is ambiguous, the ICURs were transformed into net monetary benefits (NMBs). The decision rule used was to adopt the intervention in question if the NMB is greater than zero. Given that the appropriate value of λ is unknown, λ was varied from NGN 0 to NGN 450,000. A costeffectiveness acceptability curve was generated on the basis of the distribution of NMB for each λ. A cost-effectiveness acceptability curve allows a decision maker to consider whether an intervention (PC) is cost-effective in relation to the maximum amount a decision maker is willing to pay for a QALY. A discount rate of 3% and 6% was used in sensitivity analysis [28] .
At each ceiling value for the willingness to pay for a QALY, the cost-effectiveness curve shows the probability that the treatment is cost-effective. All calculations were done in Microsoft Excel 2007 (Microsoft Corporation, Redmond, WA).
Results
Economic Outcomes
The medical and educational content of the training course was rated positively by the 17 physicians and 29 nurses: the majority 38 (82.6%) rated the content as "excellent" and the remaining 8 rated the content as "very good" or "good"; only 3 (6.5%) of them suggested little modification or changes.
The number of patients who completed the study and whose data were analyzed at 6 months and 12 months in UC and PC arms were 98 (89. were encountered. The ranges of their prices are represented. † The price in parentheses was used.
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The total drug cost was NGN 19,571 Ϯ 7,514 ($126 Ϯ $49) for UC as against NGN 17,908 Ϯ 8,549 ($116 Ϯ $55) for PC, P ¼ 0.1549. The hospital care costs for UC and PC were NGN 10,302 Ϯ 5,657 ($67 Ϯ $37) and NGN 9,766 Ϯ 4,234 ($63 ± $27), P ¼ 0.4565, respectively, while their auxiliary health care costs were NGN 4,060 Ϯ 1,675 and NGN 8,687 Ϯ 2,365 ($56 ± $15), P o 0.0001, respectively. The total cost per patient per year was NGN 50,452 Ϯ 35747 ($326 ± $231) for UC and NGN 61,075 Ϯ 43763 ($394 ± $282), P ¼ 0.1009, for PC (Table 3) .
Cost-effectiveness or cost-utility was NGN 78524.51 ($507) per QALY for UC and NGN 80,098.36 ($517) per QALY for PC, while the incremental cost and incremental QALY were NGN 10,623 ($69) and 0.12, respectively. Thus, the ICUR was NGN 88,525 ($571) per QALY.
Sensitivity Analysis
The cost-effectiveness plane that was obtained from a Monte Carlo simulation with 1000 iterations showed that 93.8% of the simulations were within the northeast quadrant, where the PC intervention resulted in gain in QALY and cost, whereas 5.6% of the simulations were in the southeast quadrant, where the PC intervention resulted in gain in QALY and reduced cost. Only 0.5% of the simulations were within the northwest quadrant, where the addition of PC resulted in loss in QALY and increased cost. The 1000 iterations produced an incremental QALY that ranged from −0.022 to 0.293 and an incremental cost that ranged from NGN −8,276.40 to NGN 28,294.27 (Fig. 1) .
The mean NMB within a willingness to pay of NGN 0 to NGN 450,000 was greater in the PC intervention whatever the willingness to pay was. This result also revealed that 90% of PC credibility interval was far above the mean of UC though the interval overlapped with about 5% of the UC (Fig. 2) .
The PC intervention led to incremental cost and incremental QALY/effect of NGN 10,623 and 0.12 QALY gained, respectively, with an associated ICUR of NGN 88525 per QALY gained. The 2 0 1 3 ) 1 8 414 .0 per QALY gained, respectively, when base costs of the cost centers were varied. The ICUR was most sensitive to variation in QALY and "total intervention-specific cost center" variable followed by that of total drug cost center (Fig. 3) . In the cost-effectiveness acceptability curve, the probability that PC was cost-effective versus UC was 95% at the threshold of NGN 250,000 per QALY gained and 52% at the threshold of NGN 88,600 per QALY gained (Fig. 4) .
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Discussion
Quality-Adjusted Life-Years
QALYs associated with PC were significantly higher than those associated with UC after 12 months. This indicates that extending this study beyond 1 year could offer more benefits to patients with diabetes in terms of QALYs gained. Some studies had demonstrated that extension of PC beyond 1 year could offer extra benefits to patients with diabetes [29, 30] .
At the end of this period, the PC intervention resulted in an incremental gain in QALYs and cost compared with the UC. This economic evaluation demonstrates that PC is the most costeffective strategy for managing patients with type 2 diabetes if the patients are willing to pay at least NGN 88,600 per QALY gained. The addition of the PC intervention to UC, as noted in this study, should be considered a highly cost-effective management option for patients with type 2 diabetes because treatments costing no more than £20,000 (NGN 4,761,905) to £30,000 (NGN 7,142,857) per QALY gained are generally considered to be costeffective [1, 31] . This PC intervention also generated greater NMBs when compared with UC; therefore, the addition of PC to UC might be considered an appropriate management option for patients with diabetes who have comorbidities where the probability or likelihood of drug-related problem is higher.
Cost-Effectiveness Plane
The cost-effectiveness plane showed that most of the simulations were within the northeast quadrant, where the addition of PC to UC resulted in gain in QALY and cost, which indicated that although the PC intervention generated more QALYs than did UC, it was more costly. The 1000 iterations showed that the 95% confidence interval of incremental QALYs and incremental cost was wide. This wide range shows that there are uncertainties surrounding both QALYs and cost. The magnitude of QALYs gained, specific intervention cost, and cost of all drugs were found to have affected the ICUR most. This provides avenues for urgent intervention to reduce the cost of drugs used for the management of diabetes and its comorbidities and an urgent institution of intervention that will improve the quality of life of patients with diabetes in Nigerian tertiary hospitals.
Net Monetary Benefit
The NMB approach provides a useful mechanism for identifying which arm of the study is most cost-effective. The NMB of additional PC over UC alone for a willingness to pay of NGN 0 to NGN 450,000, the additional PC alternative, was associated with the greater mean NMB whatever the willingness to pay was. It is interesting to note that the lowest trough (NMB) of PC was far higher than the mean of UC NMB. Addition of the PC intervention was found to be superior to UC alone in all willingness to pay, even as the willingness to pay 
increases. This result shows that if the willingness to pay is in the range of NGN 0 to NGN 450,000, there is a net monetary gain or saving of NGN 56,148 in 1 year. This amount is more than 3 months salaries of a Nigerian low-income earner based on the current NGN 18,000 minimum wage [32] . Therefore, there is need for introduction and exploitation of the PC intervention in Nigerian health facilities because this is very cost-effective with enormous NMB.
Sensitivity Analyses
This study found out that a little variation in QALY gained in PC to the tune of Ϯ10% resulted in a tremendous increase and mild lowering of the base ICUR, respectively. This result showed that the economic burden placed on patients with diabetes by 10% health deficit was enormous; therefore, interventions such as PC that would be aimed at improving the quality of life of patients and resolution/reduction of drug-related problems that would ultimately reduce the cost of drugs would certainly reduce the cost per QALY associated with diabetes. These results indicate that the additional PC intervention has a cost per QALY gained that is lower than that of UC. In the United Kingdom, interventions appear to have a high chance of acceptance by the National Institute for Clinical Excellence if their costeffectiveness is more favorable than approximately £30,000 per QALY [1] . Several other studies had classified cost-effectiveness. WHO-CHOICE classified interventions on the basis of the level of 2 0 1 3 ) 1 8 9 -1 9 8 cost-effectiveness by convention as described in the literature [33] [34] [35] . An intervention is cost saving when the intervention generates a better health outcome and costs less than the comparison intervention. The intervention is cost neutral if the ICER is 0. The intervention is very cost-effective when the ICER is more than 0 or $25,000 or less per QALY or life-year gained (LYG) while the intervention is cost-effective when the ICER is between more than $25,000 to $50,000 per QALY or LYG. The intervention is marginally cost-effective when the ICER is between more than $50,000 and $100,000 per QALY or LYG, whereas an intervention is said to be not cost-effective when the ICER is more than $100,000 per QALY or LYG.
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WHO-CHOICE published in 2005 the cost-effectiveness threshold for different regions of the world. WHO-CHOICE suggested a cost-effectiveness threshold based on gross domestic product (GDP) per capita. An intervention that produces cost per QALY gained of less than GDP per capita of the country is said to be very cost-effective while an intervention with cost per QALY gained of between one to three times the GDP per capita of the country is cost-effective. An intervention with cost per QALY gained of greater than three times the GDP per capita of the country is not cost-effective. For AFRO D where Nigeria belongs, the costeffectiveness threshold ranges from $1,695 to $5,086 [7] . With a conversion factor of NGN 155 ¼ $1, the threshold ranges from NGN 262,725 to NGN 788,330. World Bank in 2010 published a GDP per capita, considering purchasing power parity-current international $; for Nigeria, it is $2,381 (NGN 369,055:00) [34] . The associated ICUR from this study was NGN 88,525 per QALY ($571.13/QALY) gained in the PC arm, which was far lower than the GDP per capita of Nigeria in 2010 [36] .
Based on the above facts, the PC intervention with an ICUR of NGN 88,525 per QALY gained is very cost-effective although this may still not be affordable for low-income earners in relation to the NGN 18,000 minimum wage approved in Nigeria in 2011 because NGN 88,525 is about 5 months' salary of this group of Nigerians [32] .
In probabilistic sensitivity analysis, based on the costeffectiveness acceptability curve, the PC dominated UC at the threshold of NGN 88,600 per QALY gained and the probability of PC being more cost-effective approached 95% at the threshold of NGN 250,000 per QALY gained. Nevertheless, if a patient is willing to pay NGN 400,000 per QALY gained, the probability that PC is the most cost-effective option for managing patients with diabetes increases to 97%. In contrast, the probability that UC is the most cost-effective option at the threshold of NGN 400,000 per QALY gained approaches zero.
Studies of this kind must address inherent potential threats to internal validity [37, 38] . The major limitations of this study 
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were missing data, selection bias, short period of study, attrition, and consideration of only direct cost. Data on humanistic outcome measures were self-reported; however, self-reported data about diabetes status have been established to be both valid and reliable [39] . We recommend that future research studies of this kind address these limitations. This pharmaceutical intervention could be adopted for patients suffering from other chronic diseases such as HIV, hypertension, asthma, psychosis, epilepsies, and cerebrovascular and cardiovascular diseases.
Conclusions
The PC intervention was very cost-effective among patients with type 2 diabetes at the NGN 88,525 ($571.13) per QALY gained threshold, although considerable uncertainty surrounds these estimates. This study also revealed that cost incurred and QALYs gained by patients in the PC group were higher than those of their counterparts in the UC group. This indicates that the extra cost paid for extra QALYs gained is worth it because it saves future expenditures and improves the quality of life of patients. The results of this study illustrate a convincing economic rationale for improving standards of care for patients with type 2 diabetes through the PC intervention. This study provides further evidence that the cost-effectiveness of interventions to reduce the burden of diabetes-related complications compares favorably with that of other accepted uses of health care resources. The results should be of interest and used by other economists and health service researchers, and in particular should be considered by decision makers when considering the allocation of resources to diabetes care.
Cost-utility analysis thus increasingly facilitates the transparency of resource allocation processes. The usefulness of costutility analysis to decision makers explains the rapid expansion in the utilization of cost-utility analysis over the last decade. 2 0 1 3 ) 1 8 9 -1 9 8 
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